key: cord-0815240-6n2gj78j authors: Aziz, Hassan; Lashkari, Nassim; Yoon, Young Chul; Kim, Jim; Sher, Linda S.; Genyk, Yuri; Kwon, Yong K. title: EFFECTS OF COVID 19 ON SOLID ORGAN TRANSPLANTATION date: 2020-09-15 journal: Transplant Proc DOI: 10.1016/j.transproceed.2020.09.006 sha: c8563e153edb6864702113b946cee0d84001c091 doc_id: 815240 cord_uid: 6n2gj78j Background As the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a viral pandemic, data on the clinical characteristics and outcomes of patients with SARS-CoV-2 infection undergoing solid organ transplant is emerging. The objective of this systematic review is to assess currently published literature relating to the management, clinical course and outcomes of SARS-Cov-2 infection in liver, kidney and heart SOT recipients. Methods We conducted a systematic review to assess currently published literature relating to the management, clinical course and outcomes of SARS-CoV-2 infection in liver, kidney and heart solid organ transplant recipients. Articles published as of June 2020 were searched in the MEDLINE, ClinicalTrials.gov and PubMed databases. We identified 49 eligible studies with a total of 403 solid organ transplant recipients. Results Older age, male sex and pre-existing comorbidity including hypertension and/or diabetes were the most common prevailing characteristics amongst the solid organ transplant recipients. Clinical presentation ranged from mild to severe disease including multi-organ failure and death. We reported an overall mortality of 21%. Conclusions Our analysis suggests no increase in overall mortality or worse outcome in solid organ transplant recipients on immunosuppressive therapy compared with mortality in the general surgical population with SARS-CoV-2. Our findings suggest that transplant surgery and its immunosuppression effects should not be a deterrence to proper surgical care for patients in the SARS-CoV-2 era. The World Health Organization (WHO) declared the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic disease on March 11, 2020 1 , and as of September 5, 2020 , the WHO has reported 26,468,031 cases and 871,166 deaths related to SARS-CoV-2 globally 2 . Despite the extraordinary burden and stress our health care system is experiencing from the disease, the vast majority of surgical care cannot be delayed nor indefinitely held. Although current data on the clinical characteristics and outcomes of patients with SARS-CoV-2 infection undergoing surgery is rare 3 , it has been postulated that major surgery combined with SARS-Cov-2 infection may induce significant inflammatory stress, imparting an increased risk of post-operative complications and mortality. 4, 5 While many institutions are delaying elective surgeries, transplant surgeries are designated as Tier 3b, "do not postpone" by the Centers for Medicare and Medicaid Services. 6 Despite this designation, these solid organ transplant recipients (SOT) represent an extremely vulnerable surgical cohort: in frequent contact with healthcare personnel, chronically immunosuppressed state, and other concomitant medical conditions. 7, 8 The surgical management and its subsequent outcomes of SARS-Cov-2 in the SOT recipients remain unclear 9 as published reports on SARS-Cov-2 positive SOT recipients and their outcomes are limited and largely unknown. [9] [10] [11] Case reports from Asia, Europe, and the United States suggest a wide range in severity of clinical symptoms from mild and non-specific to severe respiratory distress and pneumonia. [11] [12] [13] Furthermore, reports of atypical presentations with an absence of respiratory symptoms may confound the diagnosis. [12] [13] [14] Although the American Society of Transplant Surgeons (ASTS) has recommended the best practice guidelines for transplantation in the SARS-Cov-2 era, regional and institutional variation in transplant practice continues to persist. 15, 16 In addition, limitation and regional variance in testing pose a significant J o u r n a l P r e -p r o o f difficulty in the early identification of suspected SARS-Cov-2 cases in SOT recipients. A recent survey of 111 transplant centers in the United States found a marked reduction in transplant activity despite the Tier 3b designation, a wide variation in SARS-Cov-2 testing practices, and substantial differences in the use of off label and investigational therapies for the treatment. 17 There is an urgent need to better understand the effects of SARS-Cov-2 on SOT recipients. We reviewed published literature in this rapidly evolving field to examine the current management practice, its clinical course, and the subsequent outcomes of SARS-Cov-2 infection in liver, kidney, and heart SOT recipients. We conducted a review of SARS-CoV-2 infection in SOT recipients according to the recommended Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Articles published as of June 6, 2020, were searched in the MEDLINE, ClinicalTrials.gov, and PubMed databases. A combination of the following MeSH terms was used to identify articles discussing SARS-Cov-2 infection in solid organ transplant recipients: "coronavirus," "SarsCov," "SarsCov2," "SARS-Cov-2," "Severe Acute Respiratory Syndrome," "COVID," "COVID-19," "kidney," "heart," "liver," "solid organ transplant," "transplant," "transplantation," "outcome," "immunosuppressant." Only case reports, case series, prospective and retrospective cohort studies published between 2019 to 2020 were included for final analysis and discussion. No restriction was placed on the publication status of the article. All non-English, investigational, animal, in-vitro, and cadaveric studies were excluded. In addition, book chapters, conference abstracts, review articles, management guidelines, and any article J o u r n a l P r e -p r o o f that did not include discussion of clinical course, treatment, or outcomes of SARS-Cov-2 infection in SOT recipients were also excluded. Articles were screen independently by the authors. Any disagreements were reconciled by a discussion between reviewers. Data extracted from each article included study type, year and month of publication, study country, number of patient cases, SOT type (heart, kidney, liver, or multiple), patient demographics, presence of comorbidities, immunosuppressant medications, time from transplant to initial presentation, initial presenting symptoms, treatment, clinical course, and outcomes ( Figure 1 ). Reporting of all the above variables was not a requirement for article inclusion, and any unavailable variables were documented as "not reported." Data were reported using a median and interquartile range for no-normal distributed continuous variables, absolute counts, and percentage for categorical variables. A total of 1,455 citations were identified in the initial search. After removing 211 duplicates, a total of 1,244 studies were screened by title and abstract ( Figure 2 ). Studies were excluded if they did not mention solid organ transplantation, SARS-CoV-2 infection, associated clinical course and outcomes, or did not fulfill the inclusion criteria. After excluding 1,164 studies, we completed a full-text assessment of the remaining 80 studies. Forty-nine studies were included in our final analysis after the exclusion of 31 studies at a full-text screen. Exclusion of these 31 studies at the full-text included the following reasons: discussed management and recommendations (n = 10), review articles (n = 6), discussed impact of pandemic on transplant program volumes (n = 3), descriptive studies (n = 3), non-English (n = 1), discussed non-SOT transplant (n = 1), did not discuss SOT (n = 2), discussed SARS-CoV-2 infection in J o u r n a l P r e -p r o o f transplant surgeon or donor (n = 2), discussed investigational therapy (n = 1), discussed immunologic response (n=1) or discussed non-transplant related guideline (n=1). Of the 49 studies included, 22 were case reports, 8 were case series, and 19 were cohort studies. Four studies discussed heart SOT, 25 discussed kidney SOT, 12 discussed liver SOT, and eight articles included multiple SOT. A total of 433 SOT were reported amongst all studies ( Table 1 ). The most common SOT was 252 (58.2%) kidney followed by 89 (20.6%) liver, 51 (11.8%) heart, 24 (5.5%) lung and 1 (0.2%) pancreas. Seventeen individuals (3.9%) received more than one SOT. A majority were men (n = 264, 61%). The median age of 54 (IQR: 45-64) years and the median time from the transplant of 48 (12-108) months. Overall mortality was reported as 21% (Table 2) . were reported as discharged, and 24.2% of the individuals expired during their illness. As the number of SARS-CoV-2 infections continues to grow worldwide, clinical data in SOT recipients are emerging, and our study showed overall mortality of 21% with no substantial variations among the different types of SOT ( Table 2 ). The mortality rate is in concordance with published data in terms of outcomes reported in patients undergoing acute care surgery and cancer surgery: Lei et al., Liang et al., and the COVID Surg Collaborative group reported mortality in the general surgical population of 20.5%, 39%, 23.8%, respectively. [18] [19] [20] Older age, male sex, and pre-existing conditions such as hypertension and diabetes were the most common characteristics among the SOT recipients. As predicted, we saw a broad spectrum of clinical courses ranging from having only a few mild symptoms to multi-organ failure leading to death. Despite the concerns of atypical disease presentation in immunocompromised patients, the most common presenting symptoms were similar to general population symptoms [21] [22] [23] [24] ; however, there were some variations in the incidence of the initial presenting symptoms among the different SOT types (Figure 1 ). reported in 54.3% of the patients reflecting individualized adjustment based on the severity of the disease, type of transplanted organ, interval time since transplant, and risk of rejection. 8 On a similar note, AASLD recently published management guidelines for liver transplant recipients in this COVID era 25 : continuing the routine immunosuppressive regimen in non-symptomatic recipients and reduction in immunosuppression regimen including prednisone, azathioprine or mycophenolate, and calcineurin inhibitor in symptomatic COVID-19 patients. Our study suggests that the current practice of reducing immunosuppression upon the diagnosis of the SARS-CoV-2 appears to be an appropriate measure without causing significant short-term adverse effects on graft function while maintaining a comparable patient survival to the general population. The median time from transplant to infection was 48 months in our study, as the majority of the studies focused on patients who had received SOT many years ago. Although it is a small number, we identified four individuals in which the SOT recipient contracted SARS-CoV-2 infection during the transplant perioperative period, and we found no significant difference in their initial presentation, clinical course, and outcome when compared to a cohort of patients who received a transplant more than one year ago. Although our study provides a general overview of SOT recipients' clinical course and outcomes with SARS-CoV-2 infection, we would like to recognize several limitations of the study. First, the inclusion of early case reports may be biased toward those with increased severity of disease and worse outcome leading to publication bias with overinterpretation. Second, the inclusion of a mixed transplant population and a wide heterogeneity in study inclusion criteria may not be a true representation of the study samples and therefore precluded the ability to derive causality. Furthermore, data was based on absolute counts and therefore can only be used for descriptive purposes. Lastly, a certain degree of reporting bias would have inevitably played a role as SOT recipients are trained to be more vigilant with their health conditions and have a low threshold to seek medical attention. This reporting bias could have led to more disease diagnosis in our study group than the general population. In conclusion, SARS-CoV-2 infection in SOT recipients, in general, appears to have similar presentation, clinical course, and subsequent outcomes as in the general non-SOT surgical population. We found that the patient demographics, pre-existing risk factors, and outcomes were similar within each SOT type and saw no substantial differences in mortality rate among the different SOT types. While our data show that the overall short-term survival is about the same, long-term patient survival and graft function data are needed to fully understand the impact of the COVID in transplant patients. J o u r n a l P r e -p r o o f WHO Director-General's opening remarks at the media briefing on COVID-19 -11 COVID-19) Dashboard Review of COVID-19 Outcomes in Surgical Patients Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection We Asked the Experts: Covid-19 Outbreak: Is There Still a Place for Scheduled Surgery? Effect of COVID-19 on Surgical Training Across the United States: A National Survey of General Surgery Residents American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter COVID-19 in posttransplant patients-report of 2 cases Coronavirus disease 2019: Implications of emerging infections for transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons COVID-19 in solid organ transplant recipients: a single-center case series from Spain Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve Crucial Aspects of the Management of Solid Organ Transplant Patient with COVID-19: A Narrative Review Organ Donation During the Coronavirus Pandemic: An Evolving Saga in Uncharted Waters Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study Infection in Organ Transplantation Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Infections in liver transplant recipients First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study COVID-19 in solid organ transplant recipients: A single-center case series from Spain COVID-19 in solid organ transplant recipients: Initial report from the US epicenter Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States COVID-19 in solid organ transplant recipients: a single-center experience COVID-19 in a high-risk dual heart and kidney transplant recipient Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options First cases of COVID-19 in heart transplantation from COVID-19 in a pediatric heart transplant recipient: Emergence of donor-specific antibodies Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia, Italy. Kidney Int Rep COVID-19 infection in kidney transplant recipients. Kidney International Case Report: A Kidney Transplant Patient with Mild COVID-19 Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression First case of COVID-19 in a kidney transplant recipient treated with belatacept COVID-19 in kidney transplant recipients Covid-19 and Kidney Transplantation A familial cluster, including a kidney transplant recipient COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine Identification of Kidney Transplant Recipients with Coronavirus Disease Clinical Course, Imaging Features, and Outcomes of COVID-19 in Kidney Transplant Recipients Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York COVID-19 in kidney transplant recipients Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression COVID-19 pneumonia in kidney transplant recipients-Where we are? Two distinct cases with COVID-19 in kidney transplant recipients SARS Cov-2 infection in a renal-transplanted patient: A case report COVID-19 in a Kidney Transplant Patient A catabolic state in a kidney transplant recipient with COVID-19 Coronavirus disease 2019 in renal transplant recipients: report of two cases COVID-19 in elderly kidney transplant recipients Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report Mild COVID-19 in a pediatric renal transplant recipient COVID-19 in an HIV-positive Kidney Transplant Recipient The impact of the COVID-19 outbreak on Liver Transplantation programmes in Northern Italy COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy Coronaviruses and immunosuppressed patients. The facts during the third epidemic Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation Fatal outcome in a liver transplant recipient with COVID-19 Successful Treatment of Severe COVID-19 Pneumonia in a Liver Transplant Recipient COVID-19 in Liver Transplant Recipients: An Initial Experience from the Outcome of COVID-19 in liver transplant recipients: A preliminary report from Northwestern Italy Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report Coronavirus Disease 2019 in an Orthotopic Liver Transplant Recipient Living with Human Immunodeficiency Virus Child with liver transplant recovers from COVID-19 infection. A case report